Erratum: The inhibitory action of PDCD4 in lipopolysaccharide/D- galactosamine-induced acute liver injury (Laboratory Investigation (2013) 93 (291-302) DOI: 10.1038/labinvest.2012.174);The inhibitory action of PDCD4 in lipopolysaccharide/D-galactosamine- induced acute liver injury

Laboratory Investigation

Volumn 93, Issue 3, 2013, Pages 291-302

  Wang, Xiaoyan ^a   Zhang, Lining ^a   Wei, Zengtao ^a   Zhang, Xia ^a,b   Gao, Qi ^a   Ma, Yanyan ^a   Liu, Xingli ^a,c   Jiang, Yang ^a   Liu, Xianglan ^a   Guo, Chun ^a  

^a SHANDONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b YANTAI YUHUANGDING HOSPITAL   (China)

^c QILU CHILDREN S HOSPITAL OF SHANDONG UNIVERSITY   (China)

Author keywords

acute liver injury; D GalN; inflammatory cytokines; LPS; PDCD4

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GALACTOSAMINE; I KAPPA B; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; MEMBRANE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PDCD4 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CELL INFILTRATION; CONTROLLED STUDY; ENZYME ACTIVATION; INFLAMMATORY CELL; LIVER; LIVER CELL; LIVER HEMORRHAGE; LIVER INJURY; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; WILD TYPE;

EID: 84874630090     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.75     Document Type: Erratum

References (50)

1. Lankat-Buttgereit B, Göke R. Programmed cell death protein 4 (pdcd4):A novel target for antineoplastic therapy. Biol cell 2003;95:515-519
2. Lankat-Buttgereit B, Göke. R. The tumour suppressor Pdcd4: Recent advances in the elucidation of function and regulation. Biol Cell 2009;101:309-317
3. Wang X, Wei Z, Gao F, et al. Expression and prognostic significance of PDCD4 in human epithelial ovarian carcinoma. Anticancer Res 2008;28:2991-2996
4. Wei ZT, Zhang X, Wang XY, et al. PDCD4 inhibits the malignant phenotype of ovarian cancer cells. Cancer Sci 2009;100:1408-1413
5. Zhang X, Wang X, Song X, et al. Programmed cell death 4 enhances chemosensitivity of ovarian cancer cells by activating death receptor pathway in vitro and in vivo. Cancer Sci 2010;101:2163-2170
6. Gao F, Wang X, Zhu F, et al. PDCD4 gene silencing in gliomas is associated with 5'CpG island methylation and unfavourable prognosis. J Cell Mol Med 2009;13:4257-4267
7. Gao F, Zhang P, Zhou C, et al. Frequent loss of PDCD4 expression in human glioma: Possible role in the tumorigenesis of glioma. Oncol Rep 2007;17:123-128
8. Hilliard A, Hilliard B, Zheng SJ, et al. Translational regulation of autoimmune inflammation and lymphoma genesis by programmed cell death 4. J Immunol 2006;177:8095-8102
9. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010;11:141-147
10. Yasuda M, Schmid T, Rubsamen D, et al. Downregulation of programmed cell death 4 by inflammatory conditions contributes to the generation of the tumor promoting microenvironment. Mol Carcinog 2010;49:837-848
11. Nolan JP. The role of intestinal endotoxin in liver injury: A long and evolving history. Hepatology 2010;52:1829-1835
12. Han DW. Intestinal endotoxemia as a pathogenetic mechanism in liver failure. World J Gastroenterol 2002;8:961-965
13. Nowak M, Gaines GC, Rosenberg J, et al. LPS-induced liver injury in D-galactosamine-sensitized mice requires secreted TNF-alpha and the TNF-p55 receptor. Am J Physiol Regul Integr Comp Physiol 2000;278:R1202-R1209
14. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001;13:85-94
15. Galanos C, Freudenberg MA, Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci USA 1979;76:5939-5943
16. Mignon A, Rouquet N, Fabre M, et al. LPS challenge in D-galactosamine -sensitized mice accounts for caspase-dependent fulminant hepatitis, not for septic shock. Am J Respir Crit Care Med 1999;159(4 Pt 1):1308-1315
17. Wang K, Damjanov I, Wan YJ. The protective role of pregnane X receptor in lipopolysaccharide/D-galactosamine-induced acute liver injury. Lab Invest 2010;90:257-265
18. Kuhla A, Eipel C, Abshagen K, et al. Role of the perforin/granzyme cell death pathway in D-Gal/LPS-induced inflammatory liver injury. Am J Physiol Gastrointest Liver Physiol 2009;296:G1069-G1076
19. Shang Y, Liu Y, Du L, et al. Targeted expression of uncoupling protein 2 to mouse liver increases the susceptibility to lipopolysaccharide/ galactosamine -induced acute liver injury. Hepatology 2009;50: 1204-1216
20. Li G, Qi XP, Wu XY, et al. Verapamil modulates LPS-induced cytokine production via inhibition of NF-kappa B activation in the liver. Inflamm Res 2006;55:108-113
21. Cmarik JL, Min H, Hegamyer G, et al. Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. Pro Nati Acad Sci USA 1999;96:14037-14042
22. Lankat-Buttgereit B, Gregel C, Knolle A, et al. Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II. Mol Cell Endocrinol 2004;214:149-153
23. Jansen AP, Camalier CE, Colbum NH. Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. Cancer Res 2005;65:6034-6041
24. Leupold JH, Yang HS, Colburn NH. Tumor suppressor Pdcd4 inhibits invasion/intravasation and regulates urokinase receptor (u-PAR) gene expression via Sp-transcription factors. Oncogene 2007;26:4550-4562
25. Ruan Q, Wang T, Kameswaran V, et al. The microRNA-21-PDCD4 axis prevents type 1 diabetes by blocking pancreatic beta cell death. Proc Natl Acad Sci USA 2011;108:12030-12035
26. Liu LM, Zhang JX, Luo J, et al. A role of cell apoptosis in Lipopolysaccharide (LPS)-induced nonlethal liver injury in D-galactosamine (D-GalN)-sensitized rats. Dig Dis Sci 2008;53:1316-1324
27. Afonja O, Juste D, Das S, et al. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis. Oncogene 2004;23:8135-8145
28. Zhang H, Ozaki I, Mizuta T, et al. Involvement of programmed cell death 4 in transforming growth factor-b1-induced apoptosis in human hepatocellular carcinoma. Oncogene 2006;25:6101-6112
29. Jin H, Kim TH, Hwang SK, et al. Aerosol delivery of urocanic acid-modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice. Mol Cancer Ther 2006;5:1041-1049
30. Bhatti I, Lee A, James V, et al. Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma. J Gastrointest Surg 2011;15:199-208
31. Eto K, Goto S, Nakashima W, et al. Loss of programmed cell death 4 induces apoptosis by promoting the translation of procaspase-3 mRNA. Cell Death Differ 2012;19:573-581
32. Akira S. Toll-like receptor signaling. J Biol Chem 2003;278: 38105-38108
33. Akira S, Sato S. Toll-like receptors and their signaling mechanisms. Scand J Infect Dis 2003;35:555-562
34. Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 2002;13:413-421
35. Yang HS, Jansen AP, Komar AA, et al. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation. Mol Cell Biol 2003;23:26-37
36. Loh PG, Yang HS, Walsh MA, et al. Structural basis for translational inhibition by the tumour suppressor Pdcd4. EMBO J 2009;28:274-285
37. Yang HS, Matthews CP, Clair T, et al. Tumorigenesis suppressor Pdcd4 down-regulates mitogen-activated protein kinase kinase kinase kinase 1 expression to suppress colon carcinoma cell invasion. Mol Cell Biol 2006;26:1297-1306
38. Yang HS, Knies JL, Stark C, et al. Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation. Oncogene 2003;22: 3712-3720
39. Bitomsky N, Bohm M, Klempnauer KH. Transformation suppressor protein Pdcd4 interferes with JNK-mediated phosphorylation of c-Jun and recruitment of the coactivator p300 by c-Jun. Oncogene 2004;23:7484-7493
40. Wu D, Cederbaum A. Cytochrome P4502E1 sensitizes to tumor necrosis factor alpha-induced liver injury through activation of mitogen-activated protein kinases in mice. Hepatology 2008;47:1005-1017
41. Chang L, Kamata H, Solinas G, et al. The E3 ubiquitin ligase itch couples JNK activation to TNF alpha-induced cell death by inducing c-FLIP(L) turnover. Cell 2006;124:601-613
42. Wang Y, Singh R, Lefkowitch JH, et al. Tumor necrosis factor-induced toxic liver injury results from JNK2-dependent activation of caspase-8 and the mitochondrial death pathway. J Biol Chem 2006;281: 15258-15267
43. Wajant H, Pfizenmaier K, Scheurich P. Tumor necrosis factor signaling. Cell Death Differ 2003;10:45-65
44. Haimerl F, Erhardt A, Sass G, et al. Down-regulation of the deubiquitinating enzyme ubiquitin-specific protease 2 contributes to tumor necrosis factor-alpha-induced hepatocyte survival. J Biol Chem 2009;284:495-504
45. Zhai Y, Shen XD, Gao F, et al. CXCL10 regulates liver innate immune response against ischemia and reperfusion injury. Hepatology 2008;47:207-214
46. Heinrichsdorff J, Luedde T, Perdiguero E, et al. p38 alpha MAPK inhibits JNK activation and collaborates with IkappaB kinase 2 to prevent endotoxin-induced liver failure. EMBO Rep 2008;9:1048-1054
47. Wang Q, Sun Z, Yang HS. Downregulation of tumor suppressor Pdcd4 promotes invasion and activates both beta-catenin/Tcf and AP-1-dependent transcription in colon carcinoma cells. Oncogene 2008;27:1527-1535
48. Wang Q, Zhang Y, Yang HS. Pdcd4 knockdown up-regulates MAP4K1 expression and activation of AP-1 dependent transcription through c-Myc. Biochim Biophys Acta 2012;1823:1807-1814
49. Karin M, Lin A. NF-kappaB at the crossroads of life and death. Nat Immunol 2002;3:221-227
50. Beg AA, Sha WC, Bronson RT, et al. Embryonic lethality and liver degeneration in mice lacking the RelA component of NF-kappa B. Nature 1995;376:167-170